Why Pfizer Is a Turnaround Play Worth Watching in 2026 episode artwork

EPISODE · Jun 11, 2026 · 6 MIN

Why Pfizer Is a Turnaround Play Worth Watching in 2026

from Stock Picking with Fexingo: Individual Equities, Research, and Building a Concentrated Portfolio · host Fexingo

In this episode of Stock Picking with Fexingo, Lucas and Luna dig into the case for Pfizer as a potential turnaround stock in mid-2026. With shares trading around $25, down from pandemic highs, they discuss the company's pipeline catalysts, cost-cutting efforts, and the role of its dividend in a volatile market. Lucas explains why the market's pessimism might be overdone, while Luna pushes back on the risk of patent cliffs and lack of blockbuster growth. They reference the Russell 2000's recent weakness and value stock outperformance to frame the broader backdrop. A focused look at one of the most debated names in large-cap pharma, and whether it belongs in a concentrated portfolio. #Pfizer #TurnaroundStock #Pharma #Dividend #StockPicking #ValueInvesting #Contrarian #Pipeline #PatentCliff #LargeCap #Healthcare #Biotech #Investing #FexingoBusiness #BusinessPodcast #Finance #June2026 #ConcentratedPortfolio Keep every episode free: buymeacoffee.com/fexingo

In this episode of Stock Picking with Fexingo, Lucas and Luna dig into the case for Pfizer as a potential turnaround stock in mid-2026. With shares trading around $25, down from pandemic highs, they discuss the company's pipeline catalysts, cost-cutting efforts, and the role of its dividend in a volatile market. Lucas explains why the market's pessimism might be overdone, while Luna pushes back on the risk of patent cliffs and lack of blockbuster growth. They reference the Russell 2000's recent weakness and value stock outperformance to frame the broader backdrop. A focused look at one of the most debated names in large-cap pharma, and whether it belongs in a concentrated portfolio. #Pfizer #TurnaroundStock #Pharma #Dividend #StockPicking #ValueInvesting #Contrarian #Pipeline #PatentCliff #LargeCap #Healthcare #Biotech #Investing #FexingoBusiness #BusinessPodcast #Finance #June2026 #ConcentratedPortfolio Keep every episode free: buymeacoffee.com/fexingo

NOW PLAYING

Why Pfizer Is a Turnaround Play Worth Watching in 2026

0:00 6:24

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Frequently Asked Questions

How long is this episode of Stock Picking with Fexingo: Individual Equities, Research, and Building a Concentrated Portfolio?

This episode is 6 minutes long.

When was this Stock Picking with Fexingo: Individual Equities, Research, and Building a Concentrated Portfolio episode published?

This episode was published on June 11, 2026.

What is this episode about?

In this episode of Stock Picking with Fexingo, Lucas and Luna dig into the case for Pfizer as a potential turnaround stock in mid-2026. With shares trading around $25, down from pandemic highs, they discuss the company's pipeline catalysts,...

Can I download this Stock Picking with Fexingo: Individual Equities, Research, and Building a Concentrated Portfolio episode?

Yes, you can download this episode by clicking the download button on the episode player, or subscribe to the podcast in your preferred podcast app for automatic downloads.
URL copied to clipboard!